(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Zenas Biopharma's revenue in 2025 is N/A.On average, 4 Wall Street analysts forecast ZBIO's revenue for 2025 to be $575,220,003, with the lowest ZBIO revenue forecast at $418,341,820, and the highest ZBIO revenue forecast at $1,045,854,550. On average, 2 Wall Street analysts forecast ZBIO's revenue for 2026 to be $2,136,471,675, with the lowest ZBIO revenue forecast at $717,037,879, and the highest ZBIO revenue forecast at $3,555,905,470.
In 2027, ZBIO is forecast to generate $1,786,863,416 in revenue, with the lowest revenue forecast at $1,434,912,443 and the highest revenue forecast at $2,448,136,331.